SAB Biotherapeutics, Inc. (SABS) Stock Ticker
Market factors today
Unlock the full SABS picture
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
SABS stock facts
| Ticker symbol | SABS |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $299.3M |
| CEO | Samuel J. Reich |
| Employees | 86 |
| Headquarters | Miami Beach, FL, US |
| IPO date | 2021-02-09 |
| Website | www.sab.bio |
What you can see for SABS on Tickr
Live SABS price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the SABS report.
Rankings
FAQ
What is the ticker symbol for SAB Biotherapeutics, Inc.?
The ticker symbol for SAB Biotherapeutics, Inc. is SABS, listed on the NASDAQ.
What is SABS?
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes…